# Hervé Tilly

Source: https://onco.cc/people/herve-tilly/  
OnCo record `herve-tilly` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years.

## Summary

Hervé Tilly (Rouen) was principal investigator and first author of POLARIX, which showed replacing vincristine with the CD79b ADC polatuzumab vedotin in R-CHOP reduces progression or death by 27% in previously untreated DLBCL. He has led LYSA trials for decades, including LNH03-6B in older patients, and chaired the ESMO DLBCL guidelines.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; adc; lysa
- Role: Professor of Hematology, Centre Henri Becquerel and University of Rouen; LYSA
- Specialisms: Diffuse large B-cell lymphoma; Antibody-drug conjugates; Cooperative-group trials; Lymphoma guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Tilly%20H%5BAuthor%5D%20lymphoma%20polatuzumab

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- companies: [LYSA (The Lymphoma Study Association)](https://onco.cc/companies/lysa/)
- trials: [POLARIX](https://onco.cc/trials/polarix/)
- key papers: [POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/herve-tilly.json